BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310:1427-1431. [PMID: 6201741 DOI: 10.1056/nejm198405313102204] [Cited by in Crossref: 363] [Cited by in F6Publishing: 103] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Wu M, Liu Z, Li X, Zhang A, Li N. Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma. Onco Targets Ther. 2020;13:827-840. [PMID: 32095079 DOI: 10.2147/ott.s229835] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Viegas CS, Herfs M, Rafael MS, Enriquez JL, Teixeira A, Luís IM, van 't Hoofd CM, João A, Maria VL, Cavaco S, Ferreira A, Serra M, Theuwissen E, Vermeer C, Simes DC. Gla-rich protein is a potential new vitamin K target in cancer: evidences for a direct GRP-mineral interaction. Biomed Res Int 2014;2014:340216. [PMID: 24949434 DOI: 10.1155/2014/340216] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
3 Pereira SP, Shearer MJ, Williams R, Mieli-Vergani G. Intestinal absorption of mixed micellar phylloquinone (vitamin K1) is unreliable in infants with conjugated hyperbilirubinaemia: implications for oral prophylaxis of vitamin K deficiency bleeding. Arch Dis Child Fetal Neonatal Ed 2003;88:F113-8. [PMID: 12598499 DOI: 10.1136/fn.88.2.f113] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
4 Sato M, Morimoto K, Kajihara S, Tateishi R, Shiina S, Koike K, Yatomi Y. Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Sci Rep. 2019;9:7704. [PMID: 31147560 DOI: 10.1038/s41598-019-44022-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
5 Kondo Y, Kimura O, Shimosegawa T. Significant biomarkers for the management of hepatocellular carcinoma. Clin J Gastroenterol 2015;8:109-15. [PMID: 25855582 DOI: 10.1007/s12328-015-0568-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
6 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22(1): 232-252 [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
7 Kasahara A, Hayashi N, Fusamoto H, Kawada Y, Imai Y, Yamamoto H, Hayashi E, Ogihara T, Kamada T. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci. 1993;38:2170-2176. [PMID: 7505217 DOI: 10.1007/bf01299891] [Cited by in Crossref: 59] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
8 Shen P, Si J, Li QW, Qu LL, Li LR, Yan XL, Ji GZ. Human des-γ-carboxy prothrombin: Cloning, expression and monoclonal antibody preparation. Shijie Huaren Xiaohua Zazhi 2013; 21(35): 3932-3939 [DOI: 10.11569/wcjd.v21.i35.3932] [Reference Citation Analysis]
9 Takahashi Y, Inoue T, Fukusato T. Protein induced by vitamin K absence or antagonist II-producing gastric cancer. World J Gastrointest Pathophysiol 2010; 1(4): 129-136 [PMID: 21607153 DOI: 10.4291/wjgp.v1.i4.129] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Sagar VM, Herring K, Curbishley S, Hodson J, Fletcher P, Karkhanis S, Mehrzad H, Punia P, Shah T, Shetty S, Ma YT. The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study. Oncotarget 2021;12:2338-50. [PMID: 34853657 DOI: 10.18632/oncotarget.28136] [Reference Citation Analysis]
11 Ogasawara S, Nakayama M, Akiba J, Kusano H, Yano H. Effect of sorafenib on des-γ-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line. Oncol Lett 2017;14:2170-6. [PMID: 28781657 DOI: 10.3892/ol.2017.6451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Notake T, Kobayashi A, Shinkawa H, Kawahara T, Shimizu A, Yokoyama T, Hasegawa K, Kokudo N, Matsuyama Y, Makuuchi M, Miyagawa SI. Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection. Int J Clin Oncol 2017;22:715-25. [PMID: 28303401 DOI: 10.1007/s10147-017-1114-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
14 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Xia J, Ozaki I, Matsuhashi S, Kuwashiro T, Takahashi H, Anzai K, Mizuta T. Mechanisms of PKC-Mediated Enhancement of HIF-1α Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells. Int J Mol Sci 2019;20:E1022. [PMID: 30813635 DOI: 10.3390/ijms20051022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Matsueda K, Yamamoto H, Yoshida Y, Notohara K. Hepatoid carcinoma of the pancreas producing protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP). J Gastroenterol. 2006;41:1011-1019. [PMID: 17096071 DOI: 10.1007/s00535-006-1889-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
17 Toyoda H, Kumada T, Tada T, Ito T, Maeda A, Kaneoka Y, Kagebayashi C, Satomura S. Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy. Cancer Med. 2014;3:643-651. [PMID: 24591342 DOI: 10.1002/cam4.218] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
18 Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008;8:200. [PMID: 18638391 DOI: 10.1186/1471-2407-8-200] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 5.9] [Reference Citation Analysis]
19 Yang M, Zhang X, Liu J. Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis. PLoS One 2019;14:e0225170. [PMID: 31730646 DOI: 10.1371/journal.pone.0225170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Morimoto M, Numata K, Nozaki A, Kondo M, Moriya S, Taguri M, Morita S, Konno M, Sugo A, Miyajima E, Maeda S, Tanaka K. Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations. Int J Clin Oncol 2012;17:373-9. [PMID: 21847534 DOI: 10.1007/s10147-011-0306-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
21 Kang KH, Kim JH, Kang SH, Lee BJ, Seo YS, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma. Gut Liver 2015;9:224-30. [PMID: 25473073 DOI: 10.5009/gnl14047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
22 Hasegawa K, Imamura H, Ijichi M, Matsuyama Y, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462). J Gastrointest Surg. 2008;12:858-866. [PMID: 18202893 DOI: 10.1007/s11605-007-0464-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
23 Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, Ueki T, Akizuki E, Hirata K. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol 2015; 21(16): 4933-4945 [PMID: 25945007 DOI: 10.3748/wjg.v21.i16.4933] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
24 Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015; 7(12): 1632-1651 [PMID: 26140083 DOI: 10.4254/wjh.v7.i12.1632] [Cited by in Crossref: 120] [Cited by in F6Publishing: 107] [Article Influence: 17.1] [Reference Citation Analysis]
25 Ueda N, Shiraha H, Fujikawa T, Takaoka N, Nakanishi Y, Suzuki M, Matsuo N, Tanaka S, Nishina S, Uemura M. Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines. Mol Oncol. 2008;2:241-249. [PMID: 19383345 DOI: 10.1016/j.molonc.2008.06.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
26 Murata K, Saito A, Katagiri S, Ariizumi S, Nakano M, Yamamoto M. Association of des-γ-carboxy prothrombin production and Sonazoid-enhanced ultrasound findings in hepatocellular carcinomas of different histologic grades. J Med Ultrason (2001) 2018;45:223-9. [PMID: 28828695 DOI: 10.1007/s10396-017-0816-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
27 Chen J, Wu G, Li Y. Evaluation of Serum Des-Gamma-Carboxy Prothrombin for the Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Meta-Analysis. Dis Markers. 2018;2018:8906023. [PMID: 30402170 DOI: 10.1155/2018/8906023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
28 Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050-68. [PMID: 11106350 [PMID: 11106350 DOI: 10.1093/clinchem/46.12.2050] [Cited by in Crossref: 213] [Cited by in F6Publishing: 105] [Article Influence: 10.1] [Reference Citation Analysis]
29 Shimada M, Takenaka K, Taguchi K, Fujiwara Y, Gion T, Kajiyama K, Maeda T, Shirabe K, Yanaga K, Sugimachi K. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg 1998;227:80-5. [PMID: 9445114 DOI: 10.1097/00000658-199801000-00012] [Cited by in Crossref: 120] [Cited by in F6Publishing: 112] [Article Influence: 5.0] [Reference Citation Analysis]
30 Arai T, Kobayashi A, Ohya A, Takahashi M, Yokoyama T, Shimizu A, Motoyama H, Furusawa N, Notake T, Kitagawa N. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization. Int J Clin Oncol. 2014;19:871-879. [PMID: 24218280 DOI: 10.1007/s10147-013-0634-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
31 Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol 2021;11:726213. [PMID: 34900676 DOI: 10.3389/fonc.2021.726213] [Reference Citation Analysis]
32 Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52 Suppl 3:iii1-iii8. [PMID: 12692148 DOI: 10.1136/gut.52.suppl_3.iii1] [Cited by in Crossref: 132] [Cited by in F6Publishing: 176] [Article Influence: 6.9] [Reference Citation Analysis]
33 Kusano M, Nakanishi M, Matsushima T, Sakamoto S, Sekiya C, Une Y, Suga M, Kawamura A, Koito K, Uekita Y. Changes in the plasma abnormal prothrombin level following treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1992;31 Suppl:S146-9. [PMID: 1281044 DOI: 10.1007/BF00687125] [Reference Citation Analysis]
34 Yu R, Ding S, Tan W, Tan S, Tan Z, Xiang S, Zhou Y, Mao Q, Deng G. Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population. Hepat Mon. 2015;15:e28806. [PMID: 26300931 DOI: 10.5812/hepatmon.28806v2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
35 Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15(11): 1301-1314 [PMID: 19294759 DOI: 10.3748/wjg.15.1301] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
36 Lee J, Lim YS, Lee JH, Gwak GY, Do M, Yeo I, Shin D, Han D, Park T, Kim Y. Inclusive Quantification Assay of Serum Des-γ-Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. Hepatol Commun 2021;5:1767-83. [PMID: 34558815 DOI: 10.1002/hep4.1752] [Reference Citation Analysis]
37 Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2016; 22(37): 8271-8282 [PMID: 27729734 DOI: 10.3748/wjg.v22.i37.8271] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
38 Liu Z, Wu M, Lin D, Li N. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma. J Int Med Res 2020;48:300060520902575. [PMID: 32054358 DOI: 10.1177/0300060520902575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Miyakawa T, Kajiwara Y, Shirahata A, Okamoto K, Itoh H, Ohsato K. Vitamin K contents in liver tissue of hepatocellular carcinoma patients. Jpn J Cancer Res 2000;91:68-74. [PMID: 10744046 DOI: 10.1111/j.1349-7006.2000.tb00861.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
40 Lefrere JJ, Gozin D. Use of des-gamma-carboxyprothrombin in retrospective diagnosis of hidden intoxication of anticoagulants. J Clin Pathol 1987;40:589. [PMID: 3584512 DOI: 10.1136/jcp.40.5.589-b] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.0] [Reference Citation Analysis]
41 Cui R, He J, Zhang F, Wang B, Ding H, Shen H, Li Y, Chen X. Diagnostic value of protein induced by vitamin K absence (PIVKA-II) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer. 2003;88:1878-1882. [PMID: 12799630 DOI: 10.1038/sj.bjc.6601018] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 3.6] [Reference Citation Analysis]
42 Feng X, Song P, Bie P, Jiang P, Ma K, Li X, Wang S, Wang Z, Tang W, Zheng S. Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery. Med Sci Monit 2016;22:1663-72. [PMID: 27187589 DOI: 10.12659/msm.895483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
43 Chen H, Chen S, Li S, Chen Z, Zhu X, Dai M, Kong L, Lv X, Huang Z, Qin X. Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study. Oncotarget 2017;8:90390-401. [PMID: 29163838 DOI: 10.18632/oncotarget.20153] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
44 Yu R, Tan Z, Xiang X, Dan Y, Deng G. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. BMC Cancer. 2017;17:608. [PMID: 28863782 DOI: 10.1186/s12885-017-3609-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
45 She WH, Chan ACY, Ma KW, Dai WC, Chok KSH, Cheung TT, Lo CM. Critical appraisal of TNM versus HKU staging system for postoperative prognostic evaluation of hepatocellular carcinoma. Ann Transl Med 2021;9:919. [PMID: 34350234 DOI: 10.21037/atm-20-7611] [Reference Citation Analysis]
46 Sharma B, Srinivasan R, Chawla YK, Kapil S, Saini N, Singla B, Chakraborthy A, Kalra N, Duseja A, Dhiman RK. Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int. 2010;4:569-576. [PMID: 21063479 DOI: 10.1007/s12072-010-9186-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
47 Lee Q, Yu X, Yu W. The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma. J Interv Med 2021;4:77-81. [PMID: 34805952 DOI: 10.1016/j.jimed.2021.02.004] [Reference Citation Analysis]
48 Huang JF, Takayasu K, Okada S, Shimada K, Nakanishi Y, Ikeda M. Primary hepatocellular carcinoma detected long after tumor markers and lymph node metastases--beyond our vision? Dig Dis Sci 2006;51:610-5. [PMID: 16614975 DOI: 10.1007/s10620-006-3178-z] [Reference Citation Analysis]
49 Saitta C, Raffa G, Alibrandi A, Brancatelli S, Lombardo D, Tripodi G, Raimondo G, Pollicino T. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore) 2017;96:e7266. [PMID: 28658121 DOI: 10.1097/MD.0000000000007266] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
50 Pinna AD, Iwatsuki S, Lee RG, Todo S, Madariaga JR, Marsh JW, Casavilla A, Dvorchik I, Fung JJ, Starzl TE. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997;26:877-883. [PMID: 9328308 DOI: 10.1002/hep.510260412] [Cited by in Crossref: 116] [Cited by in F6Publishing: 89] [Article Influence: 4.6] [Reference Citation Analysis]
51 Yu R, Xiang X, Tan Z, Zhou Y, Wang H, Deng G. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. Sci Rep 2016;6:35050. [PMID: 27731353 DOI: 10.1038/srep35050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
52 Toyoda H, Kikuchi K, Tsuruta Y, Hiraoka A, Tsuji K, Tanaka J. Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis. Nephrol Dial Transplant 2021;36:1097-103. [PMID: 33009910 DOI: 10.1093/ndt/gfaa165] [Reference Citation Analysis]
53 Ye X, Li C, Zu X, Lin M, Liu Q, Liu J, Xu G, Chen Z, Xu Y, Liu L, Luo D, Cao Z, Shi G, Feng Z, Deng H, Liao Q, Cai C, Liao DF, Wang J, Jin J, Cao D. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma. Hepatology. 2019;69:2489-2501. [PMID: 30672601 DOI: 10.1002/hep.30519] [Cited by in Crossref: 13] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
54 Qi F, Zhou A, Yan L, Yuan X, Wang D, Chang R, Zhang Y, Shi F, Han X, Hou J, Wei L, Zhang X. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma. J Clin Lab Anal 2020;34:e23158. [PMID: 31821607 DOI: 10.1002/jcla.23158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
55 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Mishra A, Verma M. Cancer biomarkers: are we ready for the prime time? Cancers (Basel) 2010;2:190-208. [PMID: 24281040 DOI: 10.3390/cancers2010190] [Cited by in Crossref: 97] [Cited by in F6Publishing: 73] [Article Influence: 8.1] [Reference Citation Analysis]
57 Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010;45:1272-1282. [PMID: 20625772 DOI: 10.1007/s00535-010-0278-5] [Cited by in Crossref: 106] [Cited by in F6Publishing: 98] [Article Influence: 8.8] [Reference Citation Analysis]
58 Tian Z, Yu T, Wei H, Ning N. Clinical value of LHPP-associated microRNAs combined with protein induced by vitamin K deficiency or antagonist-II in the diagnosis of alpha-fetoprotein-negative hepatocellular carcinoma. J Clin Lab Anal 2020;34:e23071. [PMID: 31693242 DOI: 10.1002/jcla.23071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
59 Jinghe X, Mizuta T, Ozaki I. Vitamin K and hepatocellular carcinoma: The basic and clinic. World J Clin Cases 2015; 3(9): 757-764 [PMID: 26380822 DOI: 10.12998/wjcc.v3.i9.757] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
60 Suzuki H, Murata K, Gotoh T, Kusano M, Okano H, Oyamada T, Yasuda Y, Imamura M, Kudo M, Mizokami M. Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma. J Gastroenterol. 2011;46:1219-1229. [PMID: 21744129 DOI: 10.1007/s00535-011-0432-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
61 Brodeur CM, Thibault P, Durand M, Perreault JP, Bisaillon M. Dissecting the expression landscape of cytochromes P450 in hepatocellular carcinoma: towards novel molecular biomarkers. Genes Cancer 2019;10:97-108. [PMID: 31258835 DOI: 10.18632/genesandcancer.190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
62 Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008;2:17-30. [PMID: 19669276 DOI: 10.1007/s12072-007-9038-x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 94] [Article Influence: 7.3] [Reference Citation Analysis]
63 Valea FA. Liver and hepatic duct cancer. Clin Obstet Gynecol 2002;45:939-51. [PMID: 12370634 DOI: 10.1097/00003081-200209000-00039] [Reference Citation Analysis]
64 Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, Lin TJ, Liao LY. Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005; 11(39): 6115-6119 [PMID: 16273636 DOI: 10.3748/wjg.v11.i39.6115] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 60] [Article Influence: 3.7] [Reference Citation Analysis]
65 Kuromatsu R, Tanaka M, Shimauchi Y, Shimada M, Tanikawa K, Watanabe K, Yokoo T. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma. J Gastroenterol. 1997;32:507-512. [PMID: 9250899 DOI: 10.1007/bf02934091] [Cited by in Crossref: 35] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
66 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 685] [Article Influence: 57.0] [Reference Citation Analysis]
67 Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:37. [PMID: 23738605 DOI: 10.1186/2046-4053-2-37] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
68 Ahmed Mohammed HF, Roberts LR. Should AFP (or any biomarkers) be used for HCC surveillance? Curr Hepatol Rep 2017;16:137-45. [PMID: 29085770 DOI: 10.1007/s11901-017-0349-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
69 Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer. 2013;2:31-39. [PMID: 24159594 DOI: 10.1159/000346220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
70 Toyoda H, Kumada T, Osaki Y, Tada T, Kaneoka Y, Maeda A. Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer Sci 2012;103:921-5. [PMID: 22320249 DOI: 10.1111/j.1349-7006.2012.02232.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
71 Benhammou JN, Lin J, Hussain SK, El-Kabany M. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res 2020;6:35. [PMID: 32685690 DOI: 10.20517/2394-5079.2020.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
72 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology 2018;68:723-50. [DOI: 10.1002/hep.29913] [78495111110.1002/hep.29913','', '1007-9327')">Reference Citation Analysis]
73 Li B, Li B, Guo T, Sun Z, Li X, Li X, Chen L, Zhao J, Mao Y. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73. Oncotarget 2017;8:80521-30. [PMID: 29113322 DOI: 10.18632/oncotarget.19298] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
74 Lee KA, Ahn JY, Lee SH, Singh Sekhon S, Kim DG, Min J, Kim YH. Aptamer-based Sandwich Assay and its Clinical Outlooks for Detecting Lipocalin-2 in Hepatocellular Carcinoma (HCC). Sci Rep 2015;5:10897. [PMID: 26039737 DOI: 10.1038/srep10897] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
75 Park SJ, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Bang HI. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore). 2017;96:e5811. [PMID: 28296720 DOI: 10.1097/md.0000000000005811] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
76 Hemken PM, Sokoll LJ, Yang X, Dai J, Elliott D, Gawel SH, Lucht M, Feng Z, Marrero JA, Srivastava S, Chan DW, Davis GJ. Validation of a novel model for the early detection of hepatocellular carcinoma. Clin Proteomics. 2019;16:2. [PMID: 30675135 DOI: 10.1186/s12014-018-9222-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
77 Tameda M, Shiraki K, Sugimoto K, Ogura S, Inagaki Y, Yamamoto N, Ikejiri M, Takei Y, Ito M, Nobori T. Des-γ-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma. Cancer Sci 2013;104:725-31. [PMID: 23480217 DOI: 10.1111/cas.12149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
78 Simon K, Serafińska S, Pazgan-Simon M. Surveillance programmes for early detection of hepatocellular carcinoma. Contemp Oncol (Pozn) 2012;16:295-9. [PMID: 23788898 DOI: 10.5114/wo.2012.30057] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
79 Nakamura J, Yazawa S, Hada T, Asao T, Naitoh H, Takenoshita S, Kosaka M, Akamatsu S, Tachikawa T, Nagamachi Y. The usefulness of anti-fucosylated antigen antibody YB-2 for diagnosis of hepatocellular carcinoma. Glycoconj J 1997;14:81-7. [PMID: 9076517 DOI: 10.1023/a:1018517116368] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
80 Hada T, Kinoshita Y, Ichimori Y, Imanishi H, Umeyama K, Amuro Y, Toyosaka A, Okamoto E, Higashino K. Establishment of an enzyme immunoassay using monoclonal antibody (HG1-219) and its application for the diagnosis of hepatocellular carcinoma. Jpn J Cancer Res 1992;83:1366-72. [PMID: 1282911 DOI: 10.1111/j.1349-7006.1992.tb02771.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
81 Hakamada K, Kimura N, Miura T, Morohashi H, Ishido K, Nara M, Toyoki Y, Narumi S, Sasaki M. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol 2008; 14(9): 1370-1377 [PMID: 18322950 DOI: 10.3748/wjg.14.1370] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
82 Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559-23580. [PMID: 24317431 DOI: 10.3390/ijms141223559] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
83 Truong BX, Yano Y, VAN VT, Seo Y, Nam NH, Trach NK, Utsumi T, Azuma T, Hayashi Y. Clinical utility of protein induced by vitamin K absence in patients with chronic hepatitis B virus infection. Biomed Rep. 2013;1:122-128. [PMID: 24648907 DOI: 10.3892/br.2012.4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
84 Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, Lau WY, Lai PB, Lam CW, Yeo W, Yu SC. Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford). 2014;16:366-372. [PMID: 23980880 DOI: 10.1111/hpb.12146] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
85 Venturelli S, Leischner C, Helling T, Burkard M, Marongiu L. Vitamins as Possible Cancer Biomarkers: Significance and Limitations. Nutrients 2021;13:3914. [PMID: 34836171 DOI: 10.3390/nu13113914] [Reference Citation Analysis]
86 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 29.2] [Reference Citation Analysis]
87 Lee SE, Schulze KJ, Cole RN, Wu LS, Yager JD, Groopman J, Christian P, West KP Jr. Biological Systems of Vitamin K: A Plasma Nutriproteomics Study of Subclinical Vitamin K Deficiency in 500 Nepalese Children. OMICS 2016;20:214-23. [PMID: 26913649 DOI: 10.1089/omi.2015.0178] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
88 Tartaglione S, Mancini P, Viggiani V, Chirletti P, Angeloni A, Anastasi E. PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma. PLoS One 2021;16:e0251656. [PMID: 34015010 DOI: 10.1371/journal.pone.0251656] [Reference Citation Analysis]
89 Megger DA, Bracht T, Kohl M, Ahrens M, Naboulsi W, Weber F, Hoffmann AC, Stephan C, Kuhlmann K, Eisenacher M, Schlaak JF, Baba HA, Meyer HE, Sitek B. Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study. Mol Cell Proteomics 2013;12:2006-20. [PMID: 23462207 DOI: 10.1074/mcp.M113.028027] [Cited by in Crossref: 81] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
90 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
91 Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013;1:10. [PMID: 24252133 DOI: 10.1186/2050-7771-1-10] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
92 Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 2021;21:401. [PMID: 33849479 DOI: 10.1186/s12885-021-08138-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, Jang MK, Lee JH, Kim JS, Kim HY, Kim DJ, Lee MS, Park CK. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2015; 21(13): 3928-3935 [PMID: 25852278 DOI: 10.3748/wjg.v21.i13.3928] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
94 Gentile I, Buonomo AR, Scotto R, Zappulo E, Carriero C, Piccirillo M, Izzo F, Rizzo M, Cerasuolo D, Borgia G, Cavalcanti E. Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. In Vivo 2017;31:695-700. [PMID: 28652441 DOI: 10.21873/invivo.11115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
95 Song T, Wang L, Xin R, Zhang L, Tian Y. Evaluation of serum AFP and DCP levels in the diagnosis of early-stage HBV-related HCC under different backgrounds. J Int Med Res 2020;48:300060520969087. [PMID: 33135527 DOI: 10.1177/0300060520969087] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Ette AI, Ndububa DA, Adekanle O, Ekrikpo U. Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control study. BMC Gastroenterol 2015;15:113. [PMID: 26341083 DOI: 10.1186/s12876-015-0344-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
97 Megger DA, Naboulsi W, Meyer HE, Sitek B. Proteome Analyses of Hepatocellular Carcinoma. J Clin Transl Hepatol 2014;2:23-30. [PMID: 26357614 DOI: 10.14218/JCTH.2013.00022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
98 Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010; 16(4): 418-424 [PMID: 20101765 DOI: 10.3748/wjg.v16.i4.418] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 110] [Article Influence: 9.3] [Reference Citation Analysis]
99 Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005;7:26-34. [PMID: 18333158 DOI: 10.1080/13651820410024049] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 11.0] [Reference Citation Analysis]
100 Ji J, Wang H, Li Y, Zheng L, Yin Y, Zou Z, Zhou F, Zhou W, Shen F, Gao C. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. PLoS One 2016;11:e0153227. [PMID: 27070780 DOI: 10.1371/journal.pone.0153227] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
101 Yang MY, Wu F, Fang F, Yang H, Zhang JF, Chen GD, Yang LY. Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma. BMC Cancer 2021;21:772. [PMID: 34217251 DOI: 10.1186/s12885-021-08491-3] [Reference Citation Analysis]
102 Andreana L, Isgrò G, Pleguezuelo M, Germani G, Burroughs AK. Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol 2009; 1(1): 48-61 [PMID: 21160965 DOI: 10.4254/wjh.v1.i1.48] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
103 Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL;  HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502. [PMID: 19852963 DOI: 10.1053/j.gastro.2009.10.031] [Cited by in Crossref: 338] [Cited by in F6Publishing: 303] [Article Influence: 26.0] [Reference Citation Analysis]
104 Lefrere JJ, Armengaud D, Leclerq M, Guillaumont M, Gozin D, Alagille D. Des-gamma-carboxyprothrombin and hepatoblastoma. J Clin Pathol 1988;41:356. [PMID: 2834424 DOI: 10.1136/jcp.41.3.356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 He XF, Wen ZB, Liu MJ, Zhang H, Li Q, He SL. Levels of plasma des-γ -carboxy protein C and prothrombin in patients with liver diseases. World J Gastroenterol 2004; 10(20): 3073-3075 [PMID: 15378798 DOI: 10.3748/wjg.v10.i20.3073] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
106 Kondo A, Kondo H, Nakagawa Y, Kameyama H, Ito H, Shimomura D, Yamanishi H, Hatanaka N, Yamamoto Y, Iwai-Kanai E, Matsuo S. Measuring serum prothrombin in patients treated with warfarin or direct oral anticoagulants. Clin Chim Acta 2021;523:224-30. [PMID: 34599901 DOI: 10.1016/j.cca.2021.09.023] [Reference Citation Analysis]
107 Ryu MR, Kang ES, Park HD. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000. J Clin Lab Anal 2019;33:e22921. [PMID: 31131509 DOI: 10.1002/jcla.22921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
108 Lee HA, Lee YR, Lee YS, Jung YK, Kim JH, An H, Yim HJ, Jeen YT, Yeon JE, Byun KS, Seo YS. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4687-4696 [PMID: 34366629 DOI: 10.3748/wjg.v27.i28.4687] [Reference Citation Analysis]
109 Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer. 2015;4:126-136. [PMID: 26020034 DOI: 10.1159/000367735] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 7.7] [Reference Citation Analysis]
110 Tsuchiya A, Ogawa M, Watanabe T, Takeuchi S, Kojima Y, Watanabe Y, Kimura N, Hayashi K, Yokoyama J, Terai S. Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma. Heliyon 2019;5:e01325. [PMID: 30911692 DOI: 10.1016/j.heliyon.2019.e01325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
111 Kato K, Iwasaki Y, Taniguchi M, Onodera K, Matsuda M, Kawakami T, Higuchi M, Kato K, Kato Y, Furukawa H. Primary colon cancer with a high serum PIVKA-II level. Int J Surg Case Rep 2015;6C:95-9. [PMID: 25528035 DOI: 10.1016/j.ijscr.2014.11.072] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
112 Ji J, Liu L, Jiang F, Wen X, Zhang Y, Li S, Lou J, Wang Y, Liu N, Guo Q, Jia Y, Gao C. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China. J Clin Lab Anal 2021;35:e24013. [PMID: 34590755 DOI: 10.1002/jcla.24013] [Reference Citation Analysis]
113 Ge T, Shen Q, Wang N, Zhang Y, Ge Z, Chu W, Lv X, Zhao F, Zhao W, Fan J, Qin W. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. Med Oncol 2015;32. [DOI: 10.1007/s12032-014-0367-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
114 Uto H, Shigehira M, Kawano T, Nagatomo H, Kuribayashi T, Taniguchi S, Koga K, Komada N, Kitamura T, Maruyama T, Tsubouchi H. Liver cell adenoma in a young man with elevated serum PIVKA-II level. J Gastroenterol 1996;31:441-5. [PMID: 8726839 DOI: 10.1007/BF02355037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
115 Pandyarajan V, Govalan R, Yang JD. Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. Int J Mol Sci 2021;22:E479. [PMID: 33418899 DOI: 10.3390/ijms22020479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
116 Carr BI, Kar S, Wang M, Wang Z. Growth inhibitory actions of prothrombin on normal hepatocytes: influence of matrix. Cell Biol Int 2007;31:929-38. [PMID: 17490900 DOI: 10.1016/j.cellbi.2007.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
117 Edwards DF, Russell RG. Probable vitamin K--deficient bleeding in two cats with malabsorption syndrome secondary to lymphocytic-plasmacytic enteritis. J Vet Intern Med 1987;1:97-101. [PMID: 3506099 DOI: 10.1111/j.1939-1676.1987.tb01995.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]